U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Stage III Intermediate Grade Adult Non-Hodgkin Lymphoma

MedGen UID:
79085
•Concept ID:
C0280158
•
Neoplastic Process
Synonym: Stage III Intermediate Grade Adult Non-Hodgkin's Lymphoma

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVStage III Intermediate Grade Adult Non-Hodgkin Lymphoma

Professional guidelines

PubMed

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity.
Sonnen R, Schmidt WP, Kuse R, Schmitz N
Br J Haematol 2002 Dec;119(3):634-9. doi: 10.1046/j.1365-2141.2002.03896.x. PMID: 12437637
Staging and treatment of non-Hodgkin's lymphoma of intermediate-grade malignancy: a retrospective study of 102 cases.
Schaafsma MR, Bieger R, Hermans J, Kluin PM, Noordijk EM, Willemze ER
Eur J Haematol 1987 Sep;39(3):252-8. doi: 10.1111/j.1600-0609.1987.tb00766.x. PMID: 3678476

Recent clinical studies

Etiology

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
Lancet Haematol 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. PMID: 30501868Free PMC Article
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematol 2016 May;3(5):e217-27. Epub 2016 Apr 6 doi: 10.1016/S2352-3026(16)00036-3. PMID: 27132696
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877
COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.
Liang R, Todd D, Chan TK, Chiu E, Lie A, Ho F
Hematol Oncol 1993 Jan-Feb;11(1):43-50. doi: 10.1002/hon.2900110106. PMID: 7686880

Diagnosis

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematol 2016 May;3(5):e217-27. Epub 2016 Apr 6 doi: 10.1016/S2352-3026(16)00036-3. PMID: 27132696
Signs, Symptoms and Complications of Non-Hodgkin's Lymphoma According to Grade and Stage in South Iran.
Dehghani M, Haddadi S, Vojdani R
Asian Pac J Cancer Prev 2015;16(8):3551-7. doi: 10.7314/apjcp.2015.16.8.3551. PMID: 25921177
Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone.
Ahmed N, Owen TE, Rubinger M, Williams G, Nugent Z, Ahmed S, Cooke A
PLoS One 2013;8(6):e65156. Epub 2013 Jun 6 doi: 10.1371/journal.pone.0065156. PMID: 23762303Free PMC Article
Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
Hagberg H, Glimelius B, Gronowitz S, Killander A, Källander C, Schröder T
Scand J Haematol 1984 Jul;33(1):59-67. doi: 10.1111/j.1600-0609.1984.tb02211.x. PMID: 6379852

Therapy

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
Lancet Haematol 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. PMID: 30501868Free PMC Article
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematol 2016 May;3(5):e217-27. Epub 2016 Apr 6 doi: 10.1016/S2352-3026(16)00036-3. PMID: 27132696
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877
MACOP-B regimen in non-Hodgkin's lymphoma.
Joensuu H, Turpeenniemi-Hujanen T
Acta Oncol 1992;31(6):657-61. doi: 10.3109/02841869209083849. PMID: 1281651

Prognosis

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
Lancet Haematol 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. PMID: 30501868Free PMC Article
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematol 2016 May;3(5):e217-27. Epub 2016 Apr 6 doi: 10.1016/S2352-3026(16)00036-3. PMID: 27132696
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877
MACOP-B regimen in non-Hodgkin's lymphoma.
Joensuu H, Turpeenniemi-Hujanen T
Acta Oncol 1992;31(6):657-61. doi: 10.3109/02841869209083849. PMID: 1281651

Clinical prediction guides

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
Lancet Haematol 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. PMID: 30501868Free PMC Article
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematol 2016 May;3(5):e217-27. Epub 2016 Apr 6 doi: 10.1016/S2352-3026(16)00036-3. PMID: 27132696
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877
Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
Hagberg H, Glimelius B, Gronowitz S, Killander A, Källander C, Schröder T
Scand J Haematol 1984 Jul;33(1):59-67. doi: 10.1111/j.1600-0609.1984.tb02211.x. PMID: 6379852

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...